COVID-19 therapeutics: Current status, access & research needs

COVID-19 Clinical Research Coalition

New effective drug treatments for COVID-19 are becoming available, while some monoclonal antibodies have lost their efficacy against the newer Omicron variants of SARS-CoV2. What is the current status of COVID-19 therapeutics, and what is the availability of these expensive medicines in low-resource settings? What research is needed to advise and guide health policies?

This Covid-19 Clinical Research Coalition webinar will convene experts to address these important questions.

Watch the recording


Welcome and introduction

Moderator: Professor Priscilla Rupali, Christian Medical College, India, and Member of  the Coalition’s Therapeutics Working Group

SARS-COV-2 / COVID therapeutics state of the art and perspectives

Professor Guido Vanham, COVID-19 Clinical Research Coalition, Belgium

Is history repeating itself? Lessons learnt from previous disease areas & access to medicines

Leena Menghaney, MSF Access Campaign, India

What does it cost to manufacture new drugs for COVID-19?

Dr Andrew Hill, University of Liverpool, United Kingdom

Current challenges to access to new therapeutics and what can be done, including what research can be done to inform policy

Dr Syed Faisal Mahmood, Aga Khan University Hospital, Pakistan, and Member of  the Coalition’s Therapeutics Working Group




23 November 2022 - 13:00 CEST
Organized by: COVID-19 Clinical Research Coalition


Online Event

Event Category